Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 14, 2018
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - November 14, 2018

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/7/18 - Abeona Granted Licenses to Develop Gene Therapies for Four Rare Disorders [Tehran Times (Iran)]
Under the terms of the agreement, Regenxbio has granted Abeona an exclusive worldwide license, with rights to sublicense, to Regenxbios NAV AAV9 vector for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 Disease and CLN3 Disease. In return for the rights, Regenxbio will receive a guaranteed $20
11/7/18 - Acacia Pharma - BARHEMSYS NDA resubmitted to FDA
Acacia Pharma has resubmitted a New Drug Application (NDA) to the FDA for its lead asset BARHEMSYS (repurposed amisulpride) for the management of post-operative nausea and vomiting (PONV). While the original complete response letter (CRL) received was unexpected, the issues related to deficiencies at the contract manufacturers responsible for produ
11/7/18 - Academy of Managed Care Pharmacy: Evidence of 'Nocebo' Effect in Patients Taking Biosimilar Products Is Unclear, According to Research in JMCP
The Academy of Managed Care Pharmacy issued the following news release:. JMCP is the scientific journal of the Academy of Managed Care Pharmacy. "Our research showed that in studies where subjects knew that they were switching from an original product to a biosimilars product, patients did not tolerate it as well as subjects in studies in which th
11/7/18 - Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, today announced that it will host a conference call at 11:00 AM Eastern Time on Wednesday, November 14, 2018 to discuss the Company s financia
11/7/18 - Acceleron Announces Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension at the 2018 American Heart Association Scientific Session
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three preclinical presentations on sotatercept in Pulmonary Arterial Hypertension at the 2018 American Heart Association Scientific Session in Chicago, IL, November
11/7/18 - Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will pr
11/7/18 - Agency Information Collection Activities; Proposed Collection; Comment Request; Individual Patient Expanded Access Applications: Form FDA 3926
Agency: " Food and Drug Administration, HHS." Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the no
11/7/18 - Agency Information Collection Activities; Proposed Collection; Comment Request; Tropical Disease Priority Review Vouchers
Agency: " Food and Drug Administration, HHS." Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the no
11/7/18 - Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer [National News Agency (Lebanon)]
Prior to Taiho, Dr. Vukovic held the CMO role at Synta Pharmaceuticals Inc. where he oversaw the company`s clinical programs, as well as biometrics, clinical operations, pharmacovigilance, regulatory and medical affairs. During his tenure at Synta, Dr. Vukovic led many early and late-stage clinical trials and their translational research activities
11/7/18 - Akorn, Inc. (NASDAQ:AKRX) Files An 8-K Results of Operations and Financial Condition
Akorn, Inc. (NASDAQ:AKRX) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition. AKORN INC ExhibitEX-99.1 2 exh-991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Akorn Provides Third Quarter 2018 Results LAKE FOREST,?To view the full exhibit click here About Akorn, Inc. (NASDAQ:AKRX) Akorn I
11/7/18 - Alkahest Appoints Elizabeth Jeffords as Chief Commercial and Strategy Officer
Alkahest, Inc., a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced the appointment of Elizabeth Jeffords as chief commercial and strategy officer. Jeffords joins Alkahest from Genentech and Roche Pharmaceuticals where she was most recently the vice president of...
11/7/18 - American Institute of Chemical Engineers and Wiley Announce the Launch of Journal of Advanced Manufacturing and Processing
The American Institute of Chemical Engineers issued the following news release:. The American Institute of Chemical Engineers and John Wiley and Sons, Inc. announce the launch of a new quarterly, peer-reviewed journal, Journal of Advanced Manufacturing and Processing. The journal's editorial team is led by Editor-in-Chief Matthew Realff and Deputy.
11/7/18 - American Society for Aesthetic Plastic Surgery Announces New Premier Partnerships With Endo Pharmaceuticals, Evolus, Inc., Sinclair Pharma
The American Society for Aesthetic Plastic Surgery today announced that Endo Pharmaceuticals, Evolus, Inc. and Sinclair Pharma are the newest additions to the Society's roster of Premier Industry Partners. Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in aesthetic...
11/7/18 - Amgen and Provention Bio Enter Development Collaboration in Celiac Disease [T-break Tech (Middle East)]
Amgen and Provention Bio, Inc., a clinical-stage biopharmaceutical company focused on immune-mediated diseases, have entered a licensing and co-development agreement for AMG 714, identified by Provention as PRV-015. Under the terms of the agreement, Provention will conduct and fund a Phase 2 b trial in NRCD and lead the next phase of development an
11/7/18 - Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018 [Sudan Tribune]
Amgen today announced the presentation of 10 scientific research abstracts, including the final report of the OSLER -1 study, evaluating the long-term safety and efficacy of Repatha in patients with hypercholesterolemia for up to five years. These analyses will be presented at the upcoming American Heart Association Scientific Sessions 2018 in Chic
11/7/18 - Amgen taps Provention Bio to develop celiac disease drug [Sudan Tribune]
Provention Bio has licensed a celiac disease drug from Amgen. Under the deal, the New Jersey- based biotech will take over the drugs development, picking up a $20 million investment from Amgen and, potentially, a $150 million phase 2 b payout. It stands to reap a $150 million milestone payment when it completes a phase 2 b trial in this population,
11/7/18 - Ampio Updates Regulatory and Clinical Status for Ampion?
Ampio Pharmaceuticals, Inc. today is providing an update of the regulatory and clinical path activities required to file a Biologics License Application for Ampion? for the treatment of severe osteoarthritis-of-the-knee. Regulatory update: Ampio designed what it thought would be a final pivotal clinical trial of Ampion, predominately under guid
11/7/18 - Antares Pharma Inc (NASDAQ:ATRS) had its Buy rating reiterated by HC Wainwright with a $4.50 price target
Analyst Ratings For Antares Pharma Inc (NASDAQ:ATRS) Today, HC Wainwright reiterated its Buy rating on Antares Pharma Inc (NASDAQ:ATRS) with a price target of $4.50. There are 3 Buy Ratings, 1 Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock. The current consensus rating on Antares Pharma Inc (NASDAQ:ATRS) is Buy with [?] The pos
11/7/18 - Apple`s Face ID Security Available in Mobile App for Clinical Trial Management [Syrian Arab News Agency]
Crucial Data Solutions announces the latest update to their native mobile app for clinical trial data collection and management. TrialKit, an eClinical platform, has incorporated Apple`s biometric technologies for user authentication. Now, iPhone users with compatible generation devices can quickly and easily sign in to the app via facial recogniti
11/7/18 - Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in "Intensive Care Medicine" and "The Lancet Respiratory Medicine"
Pierre-Francois Laterre at the 31 st Annual Congress of the European Society of Intensive Care Medicine in Paris, France. 48 patients in 13 intensive care units in five countries, including the U.S., France, Belgium, the U.K. and Spain were enrolled and treated in this multi-center, randomized, double-blinded, placebo-controlled trial. "We are del
11/7/18 - Ascletis to Present Phase II / III Clinical Study for Its All-oral HCV Treatment at the 69th Annual meeting of AASLD [Syrian Arab News Agency]
The presentation will be delivered at the 69th Annual Meeting of the American Association for the Study of Liver Diseases, being held November 9-13, 2018, in San Francisco, CA. Prof. Lai Wei, the principal investigator of the study, will present the study at 14:00 PST, Nov. 12th. In this multi-center, randomized, double blind, placebo-controlled ph
11/7/18 - AstraZeneca agrees to sell three respiratory drugs to focus on new medicines [Sudan Tribune]
Pharmaceutical giant AstraZeneca has agreed to sell three of its respiratory drugs in a $370 m deal in a bid to develop new medicines. The global drugmaker said it would sell asthma drug Alvesco and rhinitis drugs Omnaris and Zetonna to Swiss pharmaceutical company Covis Pharma, who will pay $350 m up front plus sales-related payments of $21 m over
11/7/18 - AstraZeneca Divestment of rights to Alvesco,Omnaris and Zetonna to Covis Pharma
AstraZeneca has entered into an agreement with Covis Pharma B.V. to sell its rights to the medicines Alvesco, used for the treatment of persistent asthma, and Omnaris and Zetonna, used for the treatment of nasal symptoms associated with rhinitis. Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, said:' One of our strateg
11/7/18 - Astrazeneca to sell three drugs to Swiss firm
PHARMA giant Astrazeneca will sell three of its respiratory drugs in a $370 m deal as it moves to focus on developing new medicines, the company said yesterday. The global drugmaker said it would sell asthma drug Alvesco and rhinitis drugs Omnaris and Zetonna to Swiss pharmaceutical company Covis Pharma, which will pay $350 m up front plus salesrel
11/7/18 - Asymmetrex Intensifies Campaign to Increase Awareness of the Adult Tissue Stem Cell Counting Problem
"The greatest barrier to progress in stem cell medicine is not the lack of a means to count adult tissue stem cells," corrects James L. Sherley, M.D., Ph.D., founder and director of Asymmetrex. On November 6, Sherley delivered a lecture at the 2018 10th Annual Outsourcing Clinical Trials New England Conference in Boston to relate how the need for s
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415